| Light effect on the stability of β-lapachone in solution: pathways and kinetics of degradation. | |
| | |
MedLine Citation:
|
PMID: 21827487 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Objectives The purpose of this work was to study the chemical stability of the new antitumoral β-lapachone (βLAP) to determine the degradation pathway/s of the molecule and the degradation kinetics in addition to identifying several degradation products. Method Samples of βLAP in solution were stored under conditions of darkness and illumination at 40°C at which the pseudo-first order rate constants for the βLAP degradation were determined. Furthermore, drug degraded solutions were concentrated and purified using Sephadex LH-20 and preparative thin-layer chromatography and degradation products were identified by nuclear magnetic resonance spectroscopy. Key findings The results revealed that βLAP shows two different degradation routes: hydrolysis in the dark and photolysis under the light. The βLAP exposure to light accelerated the drug degradation about 140 fold, compared with the samples stored in the absence of light. The hydrolysis produced hydroxylapachol as the main degradation product. The photolysis yielded phthalic acid, 6-hydroxy-3methylene-3H-isobenzofuran-1-one and a benzomacrolactone together with a complex mixture of other phthalate-derivatives such as 2-(2-carboxy-acetyl)-benzoic acid. Conclusions This study provides useful information for the development of βLAP dosage forms, their storage, manipulation and quality control. |
| | |
Authors:
|
Marcílio S S Cunha-Filho; Ana Estévez-Braun; Elisa Pérez-Sacau; Ma Magdalena Echezarreta-López; Ramón Martínez-Pacheco; Mariana Landín |
Related Documents
:
|
6205867 - Cochlear summating potential recorded from the external auditory meatus of normal human... 11427687 - The sensitivity of chlamydomonas photoreceptor is optimized for the frequency of cell b... 19872077 - Intensity discrimination and the stationary state. 404417 - The reactions of schistosoma mansoni miracidia to light. 2339967 - Perception of linear acceleration in weightlessness. 1166837 - Clinical applications of the threshold tracking pacemaker. |
Publication Detail:
|
Type: Journal Article Date: 2011-06-27 |
Journal Detail:
|
Title: The Journal of pharmacy and pharmacology Volume: 63 ISSN: 0022-3573 ISO Abbreviation: J. Pharm. Pharmacol. Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-08-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0376363 Medline TA: J Pharm Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 1156-60 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors. JPP © 2011 Royal Pharmaceutical Society. |
Affiliation:
|
Instituto de Ciências da Saúde, Campus Universitário de Sinop, Universidade Federal de Mato Grosso (UFMT), Avenida Alexandre Ferronato, Sinop, MT, Brazil Instituto Universitario de Bio-Orgánica 'Antonio González', Universidad de La Laguna, La Laguna, Tenerife Instituto Canario de Investigación del Cáncer (http://www.icic.es), La Laguna, Tenerife Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mechanisms of burst release from pH-responsive polymeric microparticles.
Next Document: Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A...